Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudarshan Pharma Industries's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was ₹0.47.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.97.
During the past 12 months, Sudarshan Pharma Industries's average earnings per share (NRI) Growth Rate was 37.20% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 20.00% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 38.60% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Sudarshan Pharma Industries's EPS without NRI or its related term are showing as below:
BOM:543828'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 8.8 Med: 44.8 Max: 100.2
Current: 20
During the past 10 years, Sudarshan Pharma Industries's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 100.20% per year. The lowest was 8.80% per year. And the median was 44.80% per year.
BOM:543828's 3-Year EPS without NRI Growth Rate is ranked better than 78.01% of 1255
companies
in the Chemicals industry
Industry Median: -1.5
vs BOM:543828: 20.00
Sudarshan Pharma Industries (BOM:543828) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Sudarshan Pharma Industries EPS without NRI Related Terms
Sudarshan Pharma Industries EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Sudarshan Pharma Industries's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudarshan Pharma Industries PE Ratio without NRI vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Sudarshan Pharma Industries's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Sudarshan Pharma Industries's PE Ratio without NRI falls into.
Sudarshan Pharma Industries EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.97
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudarshan Pharma Industries (BOM:543828) has a EPS without NRI of ₹0.97 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sudarshan Pharma Industries and its competitors. According to the industry distribution chart, Sudarshan Pharma Industries ranks #276 out of 1255 companies in the Chemicals industry, placing it in the top 22%.
Is Sudarshan Pharma Industries' EPS without NRI too high?
Sudarshan Pharma Industries' current EPS without NRI is ₹0.97. Based on the distribution chart, Sudarshan Pharma Industries ranks #276 out of 1255 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Sudarshan Pharma Industries has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sudarshan Pharma Industries' EPS without NRI compare to DOW?
According to the Chemicals industry distribution chart, Sudarshan Pharma Industries ranks #276 out of 1255 companies for EPS without NRI. This places Sudarshan Pharma Industries in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Chemicals company?
A good EPS without NRI depends on the Chemicals industry context. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sudarshan Pharma Industries and its competitors. Sudarshan Pharma Industries's current EPS without NRI is ₹0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudarshan Pharma Industries stock overvalued right now?
Based on GuruFocus' analysis, Sudarshan Pharma Industries (BOM:543828) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.51, compared to a current price of ₹37.16 — trading 470.8% above its estimated fair value. The current EPS without NRI is ₹0.97. Sudarshan Pharma Industries' overall GF Score™ is 69/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Sudarshan Pharma Industries (BOM:543828), the current EPS without NRI is ₹0.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sudarshan Pharma Industries (BOM:543828) Overvalued in 2026?
Based on GuruFocus' analysis, Sudarshan Pharma Industries stock appears to be overvalued.
The current stock price of ₹37.16 is trading 470.8% above its estimated GF Value™ of ₹6.51.
GuruFocus considers Sudarshan Pharma Industries to be Significantly Overvalued.
Key valuation signals for BOM:543828:
EPS without NRI: ₹0.97
GF Value™: ₹6.51 vs. price of ₹37.16 (470.8% above fair value)
No single metric tells the full story. See the BOM:543828 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sudarshan Pharma Industries Ltd operates in the pharmaceutical and chemical industries, focusing on specialty chemicals and intermediates used in pharmaceuticals, paints, food products, and adhesives. The Company has a presence domestically and internationally, participating regularly in trade fairs and exhibitions. The Company exports mainly to South East Asia, the Middle East, and North Africa. The Company also supplies generic pharmaceutical formulation as 'Make to order' for bulk supply to hospitals and related healthcare organisations. The company has one reportable segment of Specialty Chemicals.
69GF Score
Get the complete analysis for BOM:543828
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543828 has been successfully added to your 
